DelMar collaborates with PRA Health Sciences for Phase 3 Trial of VAL-083

DelMar Pharmaceuticals  announced that it has signed collaboration agreement with PRA Health Sciences for company’s Phase 3 trial of VAL-083 in recurrent glioblastoma multiforme (GBM).

DelMar Pharmaceuticals chairman and CEO, Jeffrey Bacha said that they have been working with PRA for quite some time in preparing for VAL-083’s Phase 3 study in GBM. Given their recent $9M financing, they have the resources to facilitate the initiation of their pivotal Phase 3 study of VAL-083 as a single agent treatment for GBM patients who have failed both temozolomide (Temodar) and bevacizumab (Avastin), for whom there is no currently approved therapy. They are delighted to formally engage with a CRO of the caliber and reputation of PRA to run this Phase 3 study of a treatment for a cancer indication in which there is an utmost medical need in the eyes of oncologists and the FDA.